Company intelligence / Profile preview

RareSight

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

RareSight develops patented sustained-release drug implants for rare pediatric inherited retinal diseases, with at least one new chemical entity (NCE) candidate in strategic partnership for preclinical development; no clinical trial results reported publicly.

Therapeutic areas: Ophthalmology
Modalities: Sustained release drug implantSmall molecule
Industry: Biotech

Partnerships

PolyActiva (PREZIA platform for sustained-release pro-drugs targeting pediatric inherited retinal diseases)

Beyond the preview

Go deeper on RareSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RareSight.

Explore the full profile